Oncology · Multiple MyelomaTrial Updateclinicalmid-term

Phase Ib Trial of Teclistamab and Iberdomide in Relapsed/Refractory Multiple Myeloma

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/23/2026, 6:32:06 PM

Assessment confidence: 71% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The ongoing phase Ib trial of teclistamab and iberdomide represents a significant opportunity to enhance treatment options for relapsed or refractory multiple myeloma. This combination could address unmet medical needs and strengthen competitive positioning in a crowded therapeutic landscape. Regulatory context from FDA (FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (ORIG)) supports the near-term read. Assessment grounded in 27 ranked evidence items (16 high-relevance).

Strategic Assessment

The strongest clinical anchor is Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse (ClinicalTrials.gov), entity match (iberdomide); patient population match (refractory). In Oncology · Multiple Myeloma, 6 regulatory and 5 competitive items passed relevance filtering for Teclistamab. Successful trial outcomes could lead to increased market share and revenue potential for the combination therapy, impacting existing therapies in the multiple myeloma market.

Competitive Pressure

The most relevant competitive pressure comes from U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Patients with Relapsed or Refractory Multiple Myeloma (Bristol Myers Squibb) — entity match (iberdomide); patient population match (refractory). Secondary pressure from Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (ORIG) (FDA). Regulatory pathway relevance (nda). The trial results will inform potential regulatory filings, which could expedite the approval process for this combination therapy if safety and efficacy are demonstrated.

Key Risks

Elevated medium regulatory exposure for Teclistamab could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

Successful trial outcomes could lead to increased market share and revenue potential for the combination therapy, impacting existing therapies in the multiple myeloma market.
Upside for Teclistamab may improve if Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial (ClinicalTrials.gov) delivers favorable follow-through.
Upside for Teclistamab may improve if Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma (ClinicalTrials.gov) delivers favorable follow-through.
Oncology · KRAS G12C NSCLC · Trial Update · Divarasib's positive results position it as a potential new standard of care, challenging the current market leaders sotorasib and adagrasib.
Oncology · NSCLC · Trial Update · These results position LORBRENA as a preferred standard of care over XALKORI in ALK-positive advanced NSCLC, potentially shifting treatment paradigms.

What Would Change This Assessment

This becomes more urgent if Monitor trial results for safety and efficacy data, as well as any subsequent regulatory filings.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
Verified Clinical Benefit | Cancer Accelerated Approvals
FDAmedium relevance
Regulatory pathway relevance (approval)
FDA document
View source
Ongoing | Cancer Accelerated Approvals
FDAmedium relevance
Regulatory pathway relevance (approval)
FDA document
View source

Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse
ClinicalTrials.govhigh relevance
Entity match (iberdomide); Patient population match (refractory)
FDA document
View source
Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Merck); Patient population match (refractory)
FDA document
View source
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
ClinicalTrials.govhigh relevance
Entity match (national cancer institute)
FDA document
View source
Follow-Up Evaluation for Gene-Therapy-Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials
ClinicalTrials.govhigh relevance
Entity match (national cancer institute)
FDA document
View source
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
ClinicalTrials.govhigh relevance
Entity match (national cancer institute)
FDA document
View source
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
ClinicalTrials.govhigh relevance
Entity match (national cancer institute)
FDA document
View source
Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival
ClinicalTrials.govhigh relevance
Entity match (national cancer institute)
FDA document
View source
Palliative Care Integration in Pediatric Oncology Phase 1 Clinical Trials
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Patients with Relapsed or Refractory Multiple Myeloma
Bristol Myers Squibbhigh relevance
Entity match (iberdomide); Patient population match (refractory)
FDA document
View source
Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Humanexa Signalsmedium relevance
Sponsor/company relevance (Roche)
Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC
Humanexa Signalsmedium relevance
Sponsor/company relevance (Pfizer)
Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Humanexa Signalsmedium relevance
Sponsor/company relevance (Roche)

Comparison of epcoritamab, lenalidomide, and rituximab versus usual care in relapsed/refractory follicular lymphoma.
PubMedhigh relevance
Patient population match (refractory)
FDA document
View source
An unanchored matching-adjusted indirect comparison of the efficacy of zanubrutinib versus ibrutinib for the treatment of relapsed/refractory mantle-cell lymphoma.
PubMedhigh relevance
Patient population match (refractory)
FDA document
View source
Effectiveness and safety of brentuximab vedotin-containing regimen versus standard chemotherapy in relapsed or refractory Hodgkin lymphoma: a multicenter cohort study.
PubMedhigh relevance
Patient population match (refractory)
FDA document
View source
Cost-effectiveness of ferumoxtran-enhanced macrophage-specific-MRI and PSMA-PET/CT versus ePLND for nodal staging in primary prostate cancer: a decision analysis based on updated phase-3 trial data.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Randomized phase-II trial of surufatinib plus FOLFOX/FOLFIRI versus FOLFOXIRI as second-line therapy for metastatic colorectal cancer.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Deep learning based on CD3 histological slides for prediction of colon cancer outcome: analysis of three international stage III colon cancer cohorts.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
The role of RNA modifications in cancer translational control.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Teclistamab
Iberdomide
National Cancer Institute

Commercial impact

medium

Successful trial outcomes could lead to increased market share and revenue potential for the combination therapy, impacting existing therapies in the multiple myeloma market.

Regulatory impact

medium

The trial results will inform potential regulatory filings, which could expedite the approval process for this combination therapy if safety and efficacy are demonstrated.

What to watch

Monitor trial results for safety and efficacy data, as well as any subsequent regulatory filings.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.